Episode Details
Back to Episodes
Mar 09, 2026 | Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval
Published 4 months, 2 weeks ago
Description
Novo Nordisk and Hims end legal battle, team up for branded GLP-1 telehealth distribution. BMS gets Sotyktu psoriatic arthritis approval and Phase 3 CELMoD win. Incyte receives CRL due to Novo's Indiana manufacturingissues — third company hit by same facility.
#pharma,# pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Novo Nordisk, #Hims& Hers, #GLP-1, #semaglutide, #Ozempic, #Wegovy, #obesity, #telehealth, #Bristol Myers Squibb, #Sotyktu, #deucravacitinib, #psoriatic arthritis, #CELMoD, #Incyte,#CRL, #manufacturing, #Talkspace, #UHS, #Ipsen, #Tazverik, #Xenon, #epilepsy, #Lilly, #GSK, #BMS